• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较单纯根治性前列腺切除术与在临床分期为B2(T2bNxM0)的前列腺癌中先行雄激素阻断再行根治性前列腺切除术的随机前瞻性研究。醋酸亮丙瑞林长效注射剂新辅助前列腺癌研究组。

Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

作者信息

Soloway M S, Sharifi R, Wajsman Z, McLeod D, Wood D P, Puras-Baez A

机构信息

Department of Urology, University of Miami Medical School, Florida, USA.

出版信息

J Urol. 1995 Aug;154(2 Pt 1):424-8.

PMID:7541859
Abstract

PURPOSE

Nonrandomized clinical trials have suggested that preoperative androgen deprivation can decrease the likelihood of positive surgical margins in patients with clinically localized prostate cancer. A multicenter prospective randomized trial compared radical prostatectomy alone to radical prostatectomy after 3 months of leuprolide acetate depot and flutamide in patients with stage cT2bNxM0 prostate cancer and a serum prostate specific antigen level less than 50 ng./ml.

MATERIALS AND METHODS

We randomized 149 patients to undergo androgen deprivation and 138 to undergo lymphadenectomy with (137) or without (1) prostatectomy. Of the 154 patients randomized to the surgery alone group 144 underwent pelvic node dissection with (138) or without (6) prostatectomy.

RESULTS

There was no statistically significant difference between the 2 groups in operating time, blood loss, need for transfusion, postoperative morbidity or length of hospital stay. There were 4 rectal and 2 ureteral injuries in the surgery alone group and none in the pretreatment group (p < 0.05). Patients who received androgen deprivation preoperatively had a significantly lower rate of capsule penetration (47% versus 78%, p < 0.001), positive surgical margins (18% versus 48%, p < 0.001) and tumor at the urethral margin (6% versus 17%, p < 0.01).

CONCLUSIONS

Long-term followup data will be needed to determine whether there will be a lower incidence of biochemical relapse as determined by prostate specific antigen, local recurrence or metastasis, with an improvement in patient survival.

摘要

目的

非随机临床试验表明,术前雄激素剥夺可降低临床局限性前列腺癌患者手术切缘阳性的可能性。一项多中心前瞻性随机试验比较了cT2bNxM0期前列腺癌且血清前列腺特异性抗原水平低于50 ng/ml的患者单纯根治性前列腺切除术与醋酸亮丙瑞林微球和氟他胺治疗3个月后行根治性前列腺切除术的效果。

材料与方法

我们将149例患者随机分组接受雄激素剥夺治疗,138例患者随机分组接受淋巴结清扫术,其中137例行前列腺切除术,1例不行前列腺切除术。在154例随机分组至单纯手术组的患者中,144例行盆腔淋巴结清扫术,其中138例行前列腺切除术,6例不行前列腺切除术。

结果

两组在手术时间、失血量、输血需求、术后发病率或住院时间方面无统计学显著差异。单纯手术组有4例直肠损伤和2例输尿管损伤,预处理组无损伤(p<0.05)。术前接受雄激素剥夺治疗的患者包膜穿透率(47%对78%,p<0.001)、手术切缘阳性率(18%对48%,p<0.001)和尿道切缘肿瘤发生率(6%对17%,p<0.01)显著较低。

结论

需要长期随访数据来确定前列腺特异性抗原、局部复发或转移所确定的生化复发发生率是否会降低,以及患者生存率是否会提高。

相似文献

1
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.比较单纯根治性前列腺切除术与在临床分期为B2(T2bNxM0)的前列腺癌中先行雄激素阻断再行根治性前列腺切除术的随机前瞻性研究。醋酸亮丙瑞林长效注射剂新辅助前列腺癌研究组。
J Urol. 1995 Aug;154(2 Pt 1):424-8.
2
PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.在临床B2期(T2bNxMo)前列腺癌中,雄激素阻断治疗后根治性前列腺切除标本中的前列腺特异性抗原(PSA)水平及手术切缘阳性率。亮丙瑞林长效注射剂新辅助治疗研究组。
Urology. 1997 Mar;49(3A Suppl):70-3. doi: 10.1016/s0090-4295(97)00172-6.
3
High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.新辅助雄激素剥夺治疗后行根治性前列腺切除术治疗C期前列腺癌的长期随访结果显示失败率较高。
Br J Urol. 1995 Jun;75(6):771-7. doi: 10.1111/j.1464-410x.1995.tb07389.x.
4
Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.T3期疾病的诱导雄激素剥夺联合前列腺切除术:一项II期试验中未实现基于前列腺特异性抗原的无病状态
Urology. 1996 Jun;47(6):870-7. doi: 10.1016/s0090-4295(96)00041-6.
5
Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.临床高危前列腺癌且 pT3 手术切缘阳性患者接受根治性前列腺切除术加辅助雄激素剥夺治疗的预后预测因素。
J Urol. 2012 Jul;188(1):84-90. doi: 10.1016/j.juro.2012.02.2572. Epub 2012 May 12.
6
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.cT2bNxMo期前列腺癌根治性前列腺切除术前新辅助雄激素剥夺治疗:5年结果
J Urol. 2002 Jan;167(1):112-6.
7
Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.根治性前列腺切除术前行新辅助激素治疗:病理降期及生化复发评估
J Nippon Med Sch. 2002 Oct;69(5):422-7. doi: 10.1272/jnms.69.422.
8
Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.根治性前列腺切除术前行长期新辅助激素治疗:5年随访时生化复发风险评估
Urology. 2000 Aug 1;56(2):289-94. doi: 10.1016/s0090-4295(00)00627-0.
9
Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
Urology. 1994 Feb;43(2 Suppl):52-6. doi: 10.1016/0090-4295(94)90219-4.
10
Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.前列腺癌根治术及术前有无雄激素剥夺的辅助内分泌治疗:五年结果
Int J Urol. 2004 May;11(5):295-303. doi: 10.1111/j.1442-2042.2004.00795.x.

引用本文的文献

1
A retrospective study of neoadjuvant novel hormonal therapy prior to radical prostatectomy for high-risk prostate cancer.一项关于高危前列腺癌根治性前列腺切除术前行新辅助新型激素治疗的回顾性研究。
Front Oncol. 2025 Feb 19;15:1480861. doi: 10.3389/fonc.2025.1480861. eCollection 2025.
2
Inflection points in urology as witnessed by Mark Soloway Part 2: Prostate and kidney cancers.马克·索洛韦见证的泌尿外科转折点 第二部分:前列腺癌和肾癌
Cent European J Urol. 2023;76(4):283-286. doi: 10.5173/ceju.2023.3E. Epub 2023 Nov 25.
3
Node Oligorecurrence in Prostate Cancer: A Challenge.
前列腺癌中的寡转移复发:一项挑战
Cancers (Basel). 2023 Aug 17;15(16):4159. doi: 10.3390/cancers15164159.
4
A cohort analysis of patients receiving neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy during the Covid-19 pandemic.对在新冠疫情期间接受机器人辅助腹腔镜前列腺切除术之前接受新辅助雄激素剥夺治疗的患者进行的队列分析。
J Clin Urol. 2023 Mar;16(2):131-139. doi: 10.1177/20514158211022216. Epub 2021 Jun 7.
5
A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.一种用于治疗前列腺癌的低分子量多功能治疗一体分子。
Theranostics. 2022 Feb 21;12(5):2335-2350. doi: 10.7150/thno.68715. eCollection 2022.
6
Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer-A Systematic Review and Meta-Analysis.延迟性根治性前列腺切除术与主动监测对局限性前列腺癌的影响——一项系统评价与荟萃分析
Cancers (Basel). 2021 Jun 30;13(13):3274. doi: 10.3390/cancers13133274.
7
Neoadjuvant Therapy in High-Risk Prostate Cancer.高危前列腺癌的新辅助治疗
Indian J Urol. 2020 Oct-Dec;36(4):251-261. doi: 10.4103/iju.IJU_115_20. Epub 2020 Oct 1.
8
Genitourinary cancer management during a severe pandemic: Utility of rapid communication tools and evidence-based guidelines.严重疫情期间的泌尿生殖系统癌症管理:快速沟通工具和循证指南的作用
BJUI Compass. 2020 May;1(2):45-59. doi: 10.1002/bco2.18. Epub 2020 May 25.
9
Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.雄激素反弹时间和合并症对预后不良前列腺癌患者特定原因死亡率风险的影响。
Cancer. 2018 Apr 1;124(7):1391-1399. doi: 10.1002/cncr.31217. Epub 2018 Jan 16.
10
Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer.几种晚期/转移性前列腺癌治疗方法疗效及不良反应的网状Meta分析
Oncotarget. 2017 Aug 2;8(35):59709-59719. doi: 10.18632/oncotarget.19810. eCollection 2017 Aug 29.